Download MendeleyViracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor, S.W., Kalish, V.J., Davies 2nd., J.F., Shetty, B.V., Fritz, J.E., Appelt, K., Burgess, J.A., Campanale, K.M., Chirgadze, N.Y., Clawson, D.K., Dressman, B.A., Hatch, S.D., Khalil, D.A., Kosa, M.B., Lubbehusen, P.P., Muesing, M.A., Patick, A.K., Reich, S.H., Su, K.S., Tatlock, J.H.(1997) J Med Chem 40: 3979-3985
- PubMed: 9397180 Search on PubMed
- DOI: https://doi.org/10.1021/jm9704098
- Primary Citation Related Structures:
1OHR - PubMed Abstract:
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. AG1343 (Viracept) has recently been approved for marketing for the treatment of AIDS.
- Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.
Organizational Affiliation:
